Biotechnology VALUE FUND II L.P. files SEC Form 4 disclosures for LIGAND PHARMACEUTICALS INC. They have made 58 open-market trades across 25 companies since 2005, most recently 2025-05-15.
CIK 0001102444
46 open-market purchases totalling $160.6M since 2008, against 12 sales. Across 29 scored buys the stock is up 12.2% at ninety days, and 8.4 points ahead of the S&P over the same stretch.
29 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 34% | 38% | 34% |
| Avg Move | -4.6% | +3.8% | +12.2% |
| Alpha | -9.0% | +2.3% | +8.4% |
| Scored | 29 | 29 | 29 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 100% | 86% | 86% |
| Avg Move | -11.6% | +0.8% | +8.7% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KYMR | BUY | 2023-01-11 | 2023-01-13 | $30.51 | $2.5M | +1.4% | -5.8% | -4.6% |
| XOMA | BUY | 2023-01-05 | 2023-01-09 | $18.67 | $770K | +22.3% | +8.5% | +13.7% |
| THRD | BUY | 2022-12-20 | 2022-12-22 | $4.11 | $1.7M | +0.0% | -0.5% | -4.7% |
| KYMR | BUY | 2022-08-22 | 2022-08-23 | $26.00 | $14.2M | -17.3% | -31.7% | -13.3% |
| RPTX | BUY | 2022-06-13 | 2022-06-15 | $12.73 | $3.8M | +2.4% | +8.7% | -2.3% |
| RPTX | BUY | 2022-01-19 | 2022-01-21 | $14.10 | $28.1M | +16.1% | +10.9% | -12.2% |
| OLMA | BUY | 2020-11-19 | 2020-11-20 | $19.00 | $21.6M | +5.9% | -10.4% | +4.4% |
| MRUS | BUY | 2020-06-01 | 2020-06-03 | $14.00 | $20.5M | -6.7% | -4.7% | -25.9% |
| XOMA | BUY | 2020-03-18 | 2020-03-20 | $14.52 | $129K | +19.5% | +52.8% | +43.9% |
| MRUS | BUY | 2020-01-13 | 2020-01-15 | $14.98 | $2.5M | +7.4% | +16.5% | -23.8% |
| FPRX | BUY | 2019-11-05 | 2019-11-07 | $4.00 | $3.9M | -18.0% | -1.3% | +30.2% |
| GLYC | BUY | 2019-09-05 | 2019-09-09 | $3.18 | $10.6M | +20.2% | +13.3% | +59.7% |
| INFI | BUY | 2018-12-13 | 2018-12-17 | $1.20 | $420K | -1.7% | +10.8% | +50.0% |
| XOMA | BUY | 2018-12-06 | 2018-12-10 | $14.71 | $1.8M | -19.6% | -1.8% | +0.7% |
| ARQL | SELL | 2018-04-18 | 2018-04-20 | $3.10 | $13.8M | -6.6% | +26.1% | +81.5% |
| XENE | BUY | 2017-08-14 | 2017-08-16 | $2.64 | $233K | +22.6% | +21.6% | -15.1% |
| INFI | BUY | 2016-12-28 | 2016-12-30 | $1.34 | $2.0M | +5.1% | +46.0% | +143.8% |
| INFI | BUY | 2016-12-01 | 2016-12-02 | $1.18 | $396K | -1.6% | +11.3% | +142.7% |
| LGND | SELL | 2014-03-24 | 2014-03-26 | $70.09 | $5.5M | -9.9% | -3.4% | -3.4% |
| CCXI | BUY | 2013-12-03 | 2013-12-05 | $5.01 | $951K | -48.7% | -9.1% | -9.1% |
| LGND | SELL | 2013-09-23 | 2013-09-25 | $44.50 | $16.0M | -9.9% | -3.4% | -3.4% |
| ONTY | BUY | 2013-07-31 | 2013-08-02 | $1.74 | $589K | N/A | N/A | N/A |
| LGND | BUY | 2013-01-23 | 2013-01-25 | $19.78 | $783K | -9.9% | -3.4% | -3.4% |
| CAPS | BUY | 2011-09-06 | 2011-09-08 | $0.26 | $81K | -14.9% | +11.4% | +11.4% |
| LGND | BUY | 2011-08-18 | 2011-08-22 | $11.92 | $451K | -9.9% | -3.4% | -3.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| MRUS | 338,404 | $30.5M |
| KYMR | 156,742 | $16.4M |
| CCXI | 1,210,463 | $12.9M |
| THRD | 2,332,638 | $12.5M |
| RPTX | 3,299,906 | $8.7M |
| OLMA | 361,091 | $2.4M |
| ELDN | 838,507 | $1.8M |
| GLYC | 2,955,440 | $464K |
| INFI | 6,631,136 | $296K |
| CAPS | 1,619,888 | $138K |
| ONTY | 2,413,220 | — |
| PCOP | 4,187,839 | — |
| SGXP | 3,250,200 | — |
| CRXX | 9,231,972 | — |
| TRGT | 2,435,925 | — |
| AVM | 1,141,433 | — |
| CRA | 19,035,967 | — |
| AVGN | 7,837,815 | — |
| ADLR | 5,017,551 | — |
| NPSP | 4,855,915 | — |
| Total | $1.3B |
Shares reported on the most recent Form 4, priced at the 2024-10-31 close. 10 holdings could not be priced and are excluded from the total.
| Scored | 7 | 7 | 7 |